On Friday, Edwards Lifesciences Corp (NYSE: EW) opened lower -0.36% from the last session, before settling in for the closing price of $75.92. Price fluctuations for EW have ranged from $58.93 to $96.12 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 10.28% over the last five years. Company’s average yearly earnings per share was noted 2.38% at the time writing. With a float of $579.56 million, this company’s outstanding shares have now reached $589.80 million.
The firm has a total of 19800 workers. Let’s measure their productivity. In terms of profitability, gross margin is 77.83%, operating margin of 27.19%, and the pretax margin is 27.59%.
Edwards Lifesciences Corp (EW) Insider Activity
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Edwards Lifesciences Corp is 1.74%, while institutional ownership is 84.58%. The most recent insider transaction that took place on Dec 16 ’24, was worth 185,196. In this transaction CVP, JAPAC of this company sold 2,500 shares at a rate of $74.08, taking the stock ownership to the 23,189 shares. Before that another transaction happened on Dec 16 ’24, when Company’s Officer proposed sale 2,500 for $74.08, making the entire transaction worth $185,196.
Edwards Lifesciences Corp (EW) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 2.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.00% during the next five years compared to 15.35% growth over the previous five years of trading.
Edwards Lifesciences Corp (NYSE: EW) Trading Performance Indicators
Check out the current performance indicators for Edwards Lifesciences Corp (EW). In the past quarter, the stock posted a quick ratio of 2.89. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.57. Likewise, its price to free cash flow for the trailing twelve months is 86.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 6.93, a number that is poised to hit 0.55 in the next quarter and is forecasted to reach 2.45 in one year’s time.
Technical Analysis of Edwards Lifesciences Corp (EW)
Analysing the last 5-days average volume posted by the [Edwards Lifesciences Corp, EW], we can find that recorded value of 5.88 million was better than the volume posted last year of 4.71 million. As of the previous 9 days, the stock’s Stochastic %D was 94.82%. Additionally, its Average True Range was 1.72.
During the past 100 days, Edwards Lifesciences Corp’s (EW) raw stochastic average was set at 96.22%, which indicates a significant increase from 89.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 19.02% in the past 14 days, which was lower than the 26.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $70.51, while its 200-day Moving Average is $77.96. Now, the first resistance to watch is $76.22. This is followed by the second major resistance level at $76.78. The third major resistance level sits at $77.34. If the price goes on to break the first support level at $75.10, it is likely to go to the next support level at $74.54. Should the price break the second support level, the third support level stands at $73.98.
Edwards Lifesciences Corp (NYSE: EW) Key Stats
There are currently 589,800K shares outstanding in the company with a market cap of 44.46 billion. Presently, the company’s annual sales total 6,005 M according to its annual income of 1,402 M. Last quarter, the company’s sales amounted to 1,354 M and its income totaled 3,071 M.
